The role of TCR-ζ expression in immunosuppression induced by tumour;Znaczenie ekspresji TCR-ζ w immunosupresji indukowanej przez nowotwór

Wspolczesna Onkologia

Volumn 13, Issue 5, 2009, Pages 221-226

  Sikora, Jan ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

chain expression; Cancers; T lymphocytes

Indexed keywords

CD16 ANTIGEN; CD3 ANTIGEN; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ZETA CHAIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER PATIENT; CANCER SURVIVAL; COMPLEX FORMATION; DISEASE MARKER; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; IMMUNOHISTOCHEMISTRY; MALIGNANT NEOPLASTIC DISEASE; NATURAL KILLER CELL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

EID: 73249117842     PISSN: 14282526     EISSN: 14282526     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. 264-272 peptide in the circulations of patients with head and neck cancer. Cancer Res 2002; 62: 3521-9.
2. Letsch A, Keilholz U, Schadendorf D, Nagorsen D, Schmittel A, Thiel E, Scheibenbogen C. High frequencies of circulating melanoma-reactive CD8+ T cells in patients with advanced melanoma. Int J Cancer 2000; 87: 659-64.
3. Whiteside TL. Tumor-infiltrating lymphocytes in human solid tumors. Immunol Ser 1994; 61: 137-48.
4. Whiteside TL, Parmiani G. Tumor-infiltrating lymphocytes: their phenotype, function and clinical use. Cancer Immunol Immunother 1994; 39: 15-21.
5. Saito T, Dworacki G, Gooding W, Lotze MT, Whiteside TL. Spontaneous apoptosis of CD8+ T lymphocytes in peripheral blood of patients with advanced melanoma. Clin Cancer Res 2000; 6: 1351-64.
6. Whiteside TL, Rabinowich H. The role of Fas/FasL in immunosuppression induced by human tumors. Cancer Immunol Immunother 1998; 46: 175-84.
7. Uzzo RG, Clark PE, Rayman P, Bloom T, Rybicki L, Novick AC, Bukowski RM, Finke JH. Alterations in NFκB activation in T lymphocytes of patients with renal cell carcinoma. JNCI 1999; 91: 718-21.
8. Whiteside TL. Tumor-induced death of immune cells: its mechanisms and consequences. Semin Cancer Biol 2002; 12: 43-50.
9. Gastman BR, Atarashi Y, Reichert TE, Saito T, Balkir L, Rabinowich H, Whiteside TL. Fas ligand is expressed on human squamous cell carcinomas of the head and neck and it promotes apoptosis of T lymphocytes. Cancer Res 1999; 59: 5356-64.
10. Reichert TE, Strauss L, Wagner EM, Gooding W, Whiteside TL. Signaling abnormalities and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res 2002; 8: 3137-45.
11. O'Connell J, O'Sullivan GD, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996; 184: 1075-82.
12. Sikora JJ, Dworacki GT, Kaczmarek MT, Jenek RE, Zeromski JO. Immunosuppressive mechanisms in the microenvironment of malignant pleural effusions. Cancer Detect Prev 2004; 28: 325-30.
13. Sikora J, Dworacki G, Giersz R, Zeromski J. The role of monocytes/macrophages in TCR-zeta chain downregulation and apoptosis in malignant pleural effusions. J Biol Regul Homeost Agents 2004; 18: 26-32.
14. Lai P, Rabinowich H, Crowley-Nowick PA, Bell MC, Mantovani G, Whiteside TL. Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. Clin Cancer Res 1996; 2: 161-73.
15. Finke JH, Zea AH, Stanley J, et al. Loss of T-cell receptor chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res 1993; 53: 5613-6.
16. Healy CG, Simons JW, Carducci MA, DeWeese TL, Bartkowski M, Tong KP, Bolton WE. Impaired expression and function of signal-transducing zeta chains in peripheral T cells and natural killer cells in patients with prostate cancer. Cytometry 1998; 32: 109-19.
17. Zea AH, Curti DB, Longo DL, et al. Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res 1995; 1: 1327-35.
18. Kuss I, Saito T, Johnson JT, Whiteside TL. Clinical significance of decreased zeta chain expression in peripheral blood lymphocytes of patients with head and neck cancer. Clin Cancer Res 1999; 5: 329-34.
19. Whiteside TL. Signaling defects in T lymphocytes of patients with malignancy. Cancer Immunol Immunother 1999; 48: 346-52.
20. Dworacki G, Meidenbauer N, Kuss I, Hoffmann TK, Gooding MS, Lotze M, Whiteside TL. Decrease zeta-chain expression and apoptosis in CD3+ peripheral blood T lymphocytes of patient with melanoma. Clin Cancer Res 2001; 7: 947-57.
21. - T cells have signaling defects in patients with head and neck cancer. Br J Cancer 2003; 88: 223-30.
22. Kersh EN, Shaw AS, Allen PM. Fidelity of T cell activation through multistep T cell receptor zeta phosphorylation. Science 1998; 281: 572-5.
23. Stefanová I, Saville MW, Peters C, et al. HIV infection-induced posttranslational modification of T cell signaling molecules associated with disease progression. J Clin Invest 1996; 98: 1290-7.
24. Zea AH, Ochoa MT, Ghosh P, et al. Changes in expression of signal transduction proteins in T lymphocytes of patients with leprosy. Infect Immun 1998; 66: 499.
25. Liossis SN, Ding XZ, Dennis GJ, Tsokos GC. Altered pattern of TCR/CD3-mediated protein-tyrosylphosphorylation in T cells from patients with systemic lupus erythematosus. Deficient expression of the T cell receptor zeta chain. J Clin Invest 1998; 101: 1448-57.
26. Schaeffer TM, Bell I, Fallert BA, Reinhart TA.The T-cell receptor zeta contains two homologous domains with which similar immunodeficiency virus Nef interacts and mediates down-modulation. J Virol 2000; 74: 3273-83.
27. Valitutti S, Muller S, Salio M, Lanzavecchia A. Degradation of T cell receptor (TCR)-CD3-zeta complexes after antigenic stimulation. J Exp Med 1997; 185: 1859-64.
28. Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC. Alteration in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 1992; 258: 1795-8.
29. Nakagomi H, Petersson M, Magnusson I, et al. Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res 1993; 53: 5610-2.
30. Matsuda M, Petersson M, Lenke R, Taupin JL, Magnusson I, Mellstedt H, Anderson P, Kiessling R. Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int J Cancer 1995; 61: 765-72.
31. Reichert TE, Rabinowich H, Johnson JT, Whiteside TL. Immune cells in the tumor microenvironment: mechanisms responsible for signaling and functional defects. J Immunother 1998; 21: 295-306.
32. Taylor DD, Bender DP, Gerçel-Taylor C, Stanson J, Whiteside TL. Modulation of TcR/CD3-zeta chain expression by a circulating factor derived from ovarian cancer patients. Br J Cancer 2001; 84: 1624-9.
33. Shurin GV, Shurin MR, Lotze MT, Barksdale EM. Gangliosides mediate neuroblastoma-induced inhibition of dendritic cell generation. Cancer Res 2001; 61: 363-9.
34. Esche C, Lokshin A, Shurin G, Gastman BR, Rabinowich H, Lotze MT, Shurin MR. Tumors" other immune targets: dendritic cells. J Leukoc Biol 1999; 66: 336-44.
35. Shurin MR, Gabrilovich DI. Regulation of dendritic cell system by tumor. Cancer Res Ther Control 2001; 11: 65-78.
36. Kono K, Salazar-Onfray F, Petersson M, et al. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell and natural killer cell-mediated cytoxicity. Eur J Immunol 1996; 26: 1308.
37. Atarashi Y, Kanaya H, Whiteside TL. A modified JAM assay detects apoptosis induced in activated lymphocytes by FasL+ human adherent tumor cells. J Immunol Methods 2000; 233: 179-83.
38. Gastman BR, Johnson DE, Whiteside TL, Rabinowich J. Caspase-mediated degradation of T-cell receptor zeta-chain. Cancer Res 1999; 59: 1422-7.
39. Whiteside TL. Apoptosis of immune cells in the tumor microenvironment and peripheral circulation of patients with cancer: implications for immunotherapy. Vaccine 2002; 20 (suppl 4): A46-51.
40. Reichert TE, Day R, Wagner EM, Whiteside TL. Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res 1998; 58: 5344-7.
41. Hoffmann TK, Dworacki G, Meidenbauer N, Gooding W, Johnson JT, Whiteside TL. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 2002; 8: 2553-62.
42. Schneider P, Holler N, Bodmer J, Hahne M, Frei K, Fontana A, Tschopp J. Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 1998; 187: 1205-13.
43. Kim JW, Wieckowski E, Taylor DD, Reichert TE, Whiteside TL. FasL-containing microvesicles in the circulation of patients with cancer induce apoptosis of activated T lymphocytes. J Immunother 2003; 26: 44.
44. Reichert TE, Scheuer C, Day R, Wagner W, Whiteside TL. The number of intratumoral dendritic cells and zeta-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. Cancer 2001; 91: 2136-47.
45. Zea AH, Curti BD, Longo DL, et al. Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res 1995; 11: 1327-35.
46. Kuss I, Rabinowich H, Gooding W, Edwards R, Whiteside TL. Expression of zeta in T cells prior to IL-2 therapy as a predictor of response and survival in patients with ovarian carcinoma. Cancer Biother Radiopharm 2002; 17: 631-40.
47. Rabinowich H, Banks M, Reichert TE, Logan TF, Kirkwood JM, Whiteside TL. Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy. Clin Cancer Res 1996; 2: 1263-74.
48. Farace F, Angevin E, Vanderplancke J, Escudier B, Triebel F. The decreased expression of CD3 zeta chains in cancer patients is not reversed by IL-2 administration. Int J Cancer 1994; 59: 752-5.